Doxazosin

BRAND NAMES: CARDURA; CARDURA XL

Indications

Image shows the difference between a normal and enlarged prostate:

http://www.jmb-active.com/?
activity=urology&activity_information=enlarged_prostate_treatment

Benign prostatic hyperplasia

Image from: http://idealbite.com/snuff-outthe-silent-killer-with-natures-naturalremedies-for-hypertension

Hypertension

How does BPH affect the

patient?
obstructive and irritative lower urinary tract symptoms including:
incomplete emptying
weak urine stream
urinary hesitancy
Frequency
Urgency
Nocturia
and incontinence

Who is the patient population?

100
90

Aging men have increased BPH chance.

80
70
60
50
40
30
20
10
0

31-40

51-60

Histologic BPH

61-70

81-90

Symptomatic BPH

Histologic BPH is present in approximately 8% of men aged 31 to 40, 50% of men aged 51 to 60, 70% of men aged 61 to 70, and 90% of men aged
81 to 90 (clinical key)
symptomatic (clinical) BPH is present in approximately 26% of men in the fifth decade of life, 33% of men in the sixth decade, 41% of men in the
seventh decade, and 46% of men in the eighth decade of life and beyond (clinical key)

Treatment options using

Doxazosin
(Use alone / with 5-Alpha Reducatase Inhibitors)

Patient Compliance

Side effects
Edema
Hypotension
Naseau
Vertigo
Headache
Disiness
Fatigue
Difficulty Ejaculating

Drug interactions
Contraindication: BOCEPREVIR [Systemic] (increased Doxazosin exposure)
Severe: ASENAPINE -- SELECTED ALPHA-1 ADRENERGIC ANTAGONISTS (Additive
effect)

Moderate: AVANAFIL, VARDENAFIL, TADALAFIL, NIFEDIPINE, SILDENAFIL

(Hypotension)

YOHIMBINE, MA HUANG (reduced alpha-1 adrenergic blocker

effectiveness)
MIDODRINE(may result in decreased midodrine effectiveness)

Alpha Blocker MOA

Cautions when using Alpha

Blockers
Do not prescribe if patient will have cataract
surgery.

http://www.biomedcentral.com/1471-2490/15/96
2015 Cindolo et al.

References

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons license, and indicate if changes were made. The
Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/)
applies to the data made available in this article, unless otherwise stated.

Received:
5 March 2015
Accepted:
11 September 2015
http://www.urologyhealth.org/urologic-conditions/benign-prostatic-hyperplasia-(bph)/treatment/medical-therapies
Published:
21 September 2015

http://www.micromedexsolutions.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/0F1008/ND_AppProduct/evidencexpert/DUPLICA
TIONSHIELDSYNC/484552/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/evidencexpert.DoIntegratedSearch?
SearchTerm=Doxazosin&UserSearchTerm=Doxazosin&SearchFilter=filterNone&navitem=searchALL#
https://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6787
https://www.clinicalkey.com/topics/gerontology/benign-prostatic-hyperplasia.html